Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Clinical trial NCT02627430 · WITHDRAWN

Trial details

NCT number: NCT02627430
Sponsor: National Cancer Institute (NCI)
Status: WITHDRAWN
Phase: Phase 1
Study type: INTERVENTIONAL

Adult Solid Neoplasm Estrogen Receptor Negative Fallopian Tube Serous Neoplasm HER2/Neu Negative Ovarian Serous Adenocarcinoma Ovarian Serous Tumor Primary Peritoneal Serous Adenocarcinoma Progesterone Receptor Negative Recurrent Breast Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma

Start date: 2016-03-01
Primary completion: 2019-03-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.